Clinical Trial: IL-15 Superagonist With or Without Vaccine in Biochemically Recurrent Prostate Cancer After Previous Stereotactic Body Radiation Therapy

U.S., July 8 -- ClinicalTrials.gov registry received information related to the study (NCT07686380) titled 'IL-15 Superagonist With or Without Vaccine in Biochemically Recurrent Prostate Cancer After Previous Stereotactic Body Radiation Therapy' on July 03.

Brief Summary: Background:

Biochemically recurrent prostate cancer (BCR) occurs when prostate-specific antigen (PSA) levels in the blood rise after surgery or radiation. BCR affects 30,000 to 50,000 men each year. Researchers want to know if a drug (N-803) alone or combined with a vaccine (ETBX-071) can reduce PSA in BCR prostate cancer after radiation.

Objective:

To test a study drug alone and combined with a vaccine in people with BCR prostate cancer who have been treated with targ...